Nuron Biotech宣布从Akshaya Bio购买了对抗乙肝的Chimigen多抗原疫苗的独家许可权益。此外，Nuron还获得了购买Akshaya丙肝预防和治疗产品许可的独家选择权。交易的财务条款未予以披露。
March 05, 2012 08:05 AM Eastern Time Nuron Biotech Expands Portfolio With License of Therapeutic and Prophylactic Hepatitis Vaccine Candidates
EXTON, Pa.--(BUSINESS WIRE)--Nuron Biotech Inc.
today announced it has acquired an exclusive license of technology and product rights relating to Chimigen® multi-antigen vaccines from Akshaya Bio Inc., of Edmonton, Alberta, Canada, for the hepatitis B virus (HBV). Nuron Biotech has also acquired an exclusive option to license prophylactic and therapeutic products for the hepatitis C virus (HCV). Currently, no therapeutic vaccine for HBV and no prophylactic vaccine for HCV exist on the market. Financial terms were not disclosed. [p=19, null, left]“HBV and HCV are life-altering and potentially fatal diseases, and this technology may offer a break-through for a new generation of novel therapies and preventative vaccines for patients around the world.” “These licenses and options fit incredibly well with Nuron Biotech’s strategy of identifying and in-licensing life-saving and life extending product candidates in the areas of vaccines and biologics,” said Shankar Musunuri, Ph.D., MBA, Chief Executive Officer of Nuron Biotech. “This chimeric vaccine platform (Chimigen® technology), which is used in generating both therapeutic and prophylactic vaccines, is advanced to the point where we can expect to transition our first candidate into a Phase 1 clinical trial in 2013.” “This unique technology provides Nuron Biotech with the capability to develop a highly efficient vaccine for the treatment and prevention of HBV and HCV by inducing both cellular (T cell) and humoral (B cell, antibody) immune responses to clear disease,” said Robert G. Gish, M.D., Chief of Clinical Hepatology and Professor of Clinical Medicine, University of California, San Diego. Dr. Gish is also a member of the Scientific Advisory Board for Nuron Biotech. “HBV and HCV are life-altering and potentially fatal diseases, and this technology may offer a break-through for a new generation of novel therapies and preventative vaccines for patients around the world.” Currently, 380 million people worldwide are infected with chronic HBV, which is not curable by any known therapy. More than 170 million people are infected by HCV, which is one of the leading causes of chronic liver disease, cirrhosis, liver transplantation and hepatocellular carcinoma. About Chimigen® Vaccine Technology The bifunctional nature of the chimeric multi-antigen vaccine technology represents a unique and direct approach in the therapy of chronic infectious diseases by specifically targeting antigen-presenting cell receptors with the most effective combination of viral antigen(s) and novel antibody tail fragment, the chimeric antigen. This technology offers to induce a balanced cellular as well as humoral immune response to attack chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) and may offer protection from infection. About Nuron Biotech Nuron Biotech is developing novel biologics and vaccines for the prevention and treatment of chronic neurodegenerative and infectious diseases. Our team of industry veterans is advancing products to meet unmet medical needs in the areas of multiple sclerosis, Alzheimer’s, hepatitis B and hepatitis C for patients across the globe. Our lead drug candidate, NU100 (interferon beta-1b), is a new chemical entity currently in Phase 3 for patients with multiple sclerosis.www.nuronbiotech.com.
ContactsNuron Biotech, Inc.
Richard Dinovitz, 610-968-6704
Vice President, Marketing and Business Development
or
Media:
MacDougall Biomedical Communications
Charles Liles, 781-235-3060 http://www.labbase.net/News/ShowNewsDetails-1-22-5C139962FEF17ADB.html
| 
发表于 2012-6-26 18:53
